

REMARKS


This Preliminary Amendment is being made upon entry of International Application No. PCT/US03/09039 into the U.S. National Phase of prosecution.

In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

The specification and claims 1 and 18-20 have been amended to correct an obvious error to recite that in an embodiment of the compounds of this invention, $n=2$. Applicants respectfully submit that this amendment does not add new matter, in accordance with MPEP 2163.07 and *In re Oda*. Applicants respectfully submit that one skilled in the art would recognize that the compounds exemplified in the subject specification contain a two carbon chain moiety between the fused-ring heterocyclic moiety and the nitrogen moiety of Formulas I and II- rather than a three carbon chain moiety. That is, one skilled in the art would not only recognize that the statement "In specific embodiments, $n=3$ " is erroneous, but would also recognize that the appropriate correction would be "In specific embodiments, $n=2$ ". Entry of these amendments into the record is respectfully requested.

Claims 9, 10, 24 and 31-38 have been cancelled without prejudice or disclaimer. Support for the amendment to claim 23 may be found in claim 24. Claims 4-8, 11-17, 19, 20, 23, 25 and 29 have been amended to remove multiple dependencies.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090

N:\kls\cases\p51329\natl stage\preliminary amendment.doc